Assembly Biosciences Inc (NASDAQ:ASMB) Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $45.04, for a total value of $45,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Assembly Biosciences Inc (ASMB) opened at $43.12 on Friday. Assembly Biosciences Inc has a 12-month low of $12.15 and a 12-month high of $52.37.

Several analysts have weighed in on the company. B. Riley assumed coverage on Assembly Biosciences in a research report on Friday. They issued a “neutral” rating and a $35.00 price objective for the company. ValuEngine downgraded Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. BidaskClub downgraded Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 6th. Zacks Investment Research upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research report on Wednesday, November 15th. Finally, Jefferies Group assumed coverage on Assembly Biosciences in a research report on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $39.25.

Hedge funds have recently made changes to their positions in the business. Nationwide Fund Advisors bought a new stake in Assembly Biosciences in the second quarter valued at approximately $161,000. Parametric Portfolio Associates LLC raised its holdings in shares of Assembly Biosciences by 13.6% during the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 1,203 shares in the last quarter. Legal & General Group Plc bought a new position in shares of Assembly Biosciences during the second quarter valued at approximately $212,000. Wells Fargo & Company MN bought a new position in shares of Assembly Biosciences during the second quarter valued at approximately $213,000. Finally, State of Wisconsin Investment Board bought a new position in shares of Assembly Biosciences during the second quarter valued at approximately $227,000. Hedge funds and other institutional investors own 62.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.watchlistnews.com/assembly-biosciences-inc-asmb-director-sells-45040-00-in-stock/1797379.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.